DaVita HealthCare Partners Inc (DVA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
DaVita HealthCare Partners Inc stock (DVA) is currently trading at $155.11. DaVita HealthCare Partners Inc PE ratio is 16.13. DaVita HealthCare Partners Inc PS ratio (Price-to-Sales) is 0.75. Analyst consensus price target for DVA is $151.71. WallStSmart rates DVA as Moderate Buy.
- DVA PE ratio analysis and historical PE chart
- DVA PS ratio (Price-to-Sales) history and trend
- DVA intrinsic value — DCF, Graham Number, EPV models
- DVA stock price prediction 2025 2026 2027 2028 2029 2030
- DVA fair value vs current price
- DVA insider transactions and insider buying
- Is DVA undervalued or overvalued?
- DaVita HealthCare Partners Inc financial analysis — revenue, earnings, cash flow
- DVA Piotroski F-Score and Altman Z-Score
- DVA analyst price target and Smart Rating
DaVita HealthCare Partners Inc
📊 No data available
Try selecting a different time range
DVA Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · DaVita HealthCare Partners Inc (DVA)
DVA is trading near its Graham intrinsic value of $163.40, suggesting the stock is reasonably priced at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
DaVita HealthCare Partners Inc (DVA) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, return on equity. Concerns around price/book. Overall metrics suggest strong investment potential with favorable risk/reward.
DaVita HealthCare Partners Inc (DVA) Key Strengths (5)
Growing significantly faster than its price suggests
Every $100 of shareholder equity generates $65 in profit
Paying less than $1 for every $1 of annual revenue
Large-cap company with substantial market presence
52.89% held by institutions, strong professional interest
Supporting Valuation Data
DaVita HealthCare Partners Inc (DVA) Areas to Watch (5)
Very expensive at 21.6x book value
Modest revenue growth at 9.90%
Modest earnings growth at 6.50%
Thin profit margins with limited profitability
Decent operational efficiency, solid but not exceptional
DaVita HealthCare Partners Inc (DVA) Detailed Analysis Report
Overall Assessment
This company scores 66/100 in our Smart Analysis, earning a B- grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.4/10) while 5 fall into concern territory (avg 4.0/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on PEG Ratio, Return on Equity, Price/Sales. Valuation metrics including PEG Ratio (0.56), Price/Sales (0.75) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 64.80%.
The Bear Case
The primary concerns are Price/Book, Revenue Growth, EPS Growth. Some valuation metrics including Price/Book (21.63) suggest expensive pricing. Growth concerns include Revenue Growth at 9.90%, EPS Growth at 6.50%, which may limit upside. Profitability pressure is visible in Operating Margin at 15.20%, Profit Margin at 5.47%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 64.80% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 9.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Return on Equity) and negatives (Price/Book, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DVA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
DVA's Price-to-Sales ratio of 0.75x trades at a 16% premium to its historical average of 0.65x (68th percentile). The current valuation is 44% below its historical high of 1.35x set in Mar 2006, and 189% above its historical low of 0.26x in Nov 2017.
WallStSmart Analysis Synopsis
Data-driven financial summary for DaVita HealthCare Partners Inc (DVA) · HEALTHCARE › MEDICAL CARE FACILITIES
The Big Picture
DaVita HealthCare Partners Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 13.6B with 10% growth year-over-year. Profit margins are thin at 5.5%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 64.8% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 395M in free cash flow and 541M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can DaVita HealthCare Partners Inc push profit margins above 15% as the business scales?
Sector dynamics: monitor MEDICAL CARE FACILITIES industry trends, competitive moves, and regulatory changes that could impact DaVita HealthCare Partners Inc.
Bottom Line
DaVita HealthCare Partners Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(47 last 3 months)
| Insider | Type | Shares |
|---|---|---|
BERKSHIRE, HATHAWAY INC 10% Owner | Sell | -1,658,480 |
Data sourced from SEC Form 4 filings
Last updated: 11:32:41 AM
About DaVita HealthCare Partners Inc(DVA)
NYSE
HEALTHCARE
MEDICAL CARE FACILITIES
USA
DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.